In vitro susceptibility of Mycobacterium tuberculosis to a new macrolide antibiotic: RU-28965.
The in vitro susceptibility of Mycobacterium tuberculosis to a new macrolide antibiotic RU-28965, alone and in combination with rifampicin or isoniazid, was studied by the agar dilution method. At a concentration of 4 mg/l, or lower, of RU-28965, 90% of the strains were inhibited. A synergistic effect with both rifampicin and with isoniazid was demonstrated.
D000904:Antibiotics, Antitubercular / Q000494:pharmacology*; D004338:Drug Combinations; D004353:Drug Evaluation, Preclinical; D007538:Isoniazid / Q000494:pharmacology; D007933:Leucomycins / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D012293:Rifampin / Q000494:pharmacology
D000904:Antibiotics, Antitubercular; D004338:Drug Combinations; D007933:Leucomycins; D007538:Isoniazid; D012293:Rifampin